Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) Tha…

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

MULTICENTER, RANDOMIZED, ACTIVE COMPARATOR-CONTROLLED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, DOSE-FINDING PHASE 2 STUDY TO COMPARE THE SAFETY OF THE ORAL FXIA INHIBITOR BAY 2433334 TO APIXABAN IN PATIENTS WITH ATRIAL FIBRILLATION (PACIFIC-AF)

Intervention/treatment:
BAY 2433334
Medical condition:
ATRIAL FIBRILLATION
Protocol code:
19765
Control number:
231701
Status:
Closed
Approved:
December 05, 2019
Date Completed:
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT04218266
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
45 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Therapeutic Area Head
Organization
Bayer AG
Phone:
(+) 1-888-8422937
Sponsor
BAYER INC

Locations

Nova Scotia

Queen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia, B3H 3A7

Quebec

Clinique Sante Cardio MC
Montreal, Quebec, H1T 3Y7
Institut universitaire de cardiologie et de pneumologie
Ste-Foy, Quebec, G1V 4G5
Montreal Heart Institute
Montreal, Quebec, H1T 1C8

Results

See the results from the trial NCT04218266. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?